New South Capital Management Inc. decreased its position in Avantor, Inc. (NYSE:AVTR – Free Report) by 49.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 750,808 shares of the company’s stock after selling 721,809 shares during the quarter. New South Capital Management Inc. owned 0.11% of Avantor worth $11,300,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in AVTR. Elevation Wealth Partners LLC raised its position in shares of Avantor by 72.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock valued at $42,000 after acquiring an additional 1,176 shares in the last quarter. Root Financial Partners LLC acquired a new position in Avantor in the third quarter worth $57,000. Nisa Investment Advisors LLC boosted its holdings in Avantor by 40.8% in the third quarter. Nisa Investment Advisors LLC now owns 4,938 shares of the company’s stock worth $74,000 after purchasing an additional 1,431 shares during the period. IFP Advisors Inc boosted its holdings in Avantor by 901.4% in the second quarter. IFP Advisors Inc now owns 5,858 shares of the company’s stock worth $58,000 after purchasing an additional 5,273 shares during the period. Finally, State of Wyoming bought a new stake in Avantor during the second quarter valued at $74,000. 95.08% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
AVTR has been the topic of a number of research reports. Barclays increased their target price on shares of Avantor from $15.00 to $16.00 and gave the stock an “underweight” rating in a report on Thursday, October 29th. Deutsche Bank reaffirmed a “hold” rating and issued a $17.00 price target on shares of Avantor in a report on Thursday, October 29th. Morgan Stanley boosted their price objective on shares of Avantor from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 13th. Robert W. Baird increased their price objective on shares of Avantor from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Finally, Royal Bank Of Canada increased their price objective on shares of Avantor from $14.00 to $17.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 28th. Two investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Avantor has an average rating of “Hold” and a consensus target price of $14.77.
Get Our Latest Research Report on Avantor
Avantor Trading Up 1.2%
NYSE:AVTR opened at $15.76 on Thursday. The firm has a market capitalization of $10.68 billion, a P/E ratio of 18.99, a P/E/G ratio of 7.04 and a beta of 0.95. The business has a 50 day simple moving average of $15.68 and a 200 day simple moving average of $11.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.89 and a quick ratio of 1.27. Avantor, Inc. has a 12-month low of $7.26 and a 12-month high of $17.45.
Avantor (NYSE:AVTR – Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.01. The firm had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.64 billion. Avantor had a return on equity of 9.79% and a net margin of 5.08%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the company earned $0.22 earnings per share. Equities research analysts predict that Avantor, Inc. will post 0.82 EPS for the current year.
About Avantor
Avantor, Inc. is a global provider of products and services used in life sciences, advanced technology and applied materials. Its customers include biopharmaceutical and healthcare companies, laboratories, universities and manufacturers. The company supplies chemicals, reagents, laboratory consumables and equipment, as well as materials used in biopharmaceutical production. Avantor also provides services such as procurement, inventory management and support for laboratory and production operations.
Featured Articles
- Five stocks we like better than Avantor
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
